Eye professionals clinic (14-S DHA Phase 2 Ghazi road)
Lahore, Punjab Province, Pakistan
NCT Number: NCT07001124
The comparative efficacy of the duochrome test versus +1 blur test in detecting refractive errors across different ages remains under-explored in current ophthalmic research. While the duochrome test is widely used to refine prescriptions, its standalone effectiveness compared to +1 blur test based refraction has not been thoroughly investigated.
This study is active but is not currently recruiting participants.
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Lahore, Punjab Province, Pakistan
This study aims to evaluate the efficacy, accuracy, and reliability of the duochrome test in identifying refractive errors, including myopia and hyperopia across various ages. Refractive errors, including myopia, hyperopia, and astigmatism, are leading causes of visual impairment, requiring precise diagnostic tools. The duochrome test utilizes chromatic aberration to refine prescriptions, whereas the +1 blur test assesses spherical correction accuracy. Despite their clinical use, direct comparative studies remain limited. A total of 33 participants with estimated 10% dropout randomly assigned to undergo both tests. Groups will be based on different ages, Group A (18-35 years)and group B (36-60 years) ..both test (Duochrome test and +1 blur test) will apply on every patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The participant is seated at a standard testing distance (typically 6 meters or 20 feet). A duochrome chart with black letters on a split red-green background is presented.
After determining the subjective refraction, a +1.00 diopter (DS) lens is added to the final prescription. The participant is asked to read the distance visual acuity (VA) chart. The expectation is that the visual acuity should drop to 4 lines on Snellen chart (6/24) when the +1.00 DS lens is added. If VA reduces to 6/24: Indicates that the refraction is not over-minused or over-plussed (proper end point of refraction). If VA remains better than 6/24: Suggests the patient was still accommodating, possibly leading to over-minus (in myopes) or under-plus (in hyperopes) and the refraction should be re-evaluated.
Time frame: 12 Months
Scores on all activities that the person performed or did not perform because of vision were then averaged, yielding a value from 0 to 4. This value was multiplied by 25, giving a final score from 0 to 100. A score of 100 indicates able to do all applicable activities score of 0 indicates unable to do all applicable activities because of vision
Time frame: 12 Months
Adding a +1.00 diopter (DS) lens to a patient's final refraction and measuring their distance visual acuity (VA). There are 4 questions with 5 different options ranging from 0-4. minimum score is 0 and maximum score is 16 with spherical correction.
Time frame: 12 Months
A duochrome test chart .There are 4 questions with 5 different options ranging from 0-4. minimum score is 0 and maximum score is 16 with spherical correction.
Superior University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07036835
Eye Diseases, Refractive Errors
Sydney, New South Wales, Australia
View Trial DetailsNCT04740593
Amblyopia, Brain Diseases
Rotterdam, Netherlands
View Trial DetailsNCT06913491
Eye Diseases, Refractive Errors
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05550740
Eye Diseases, High Myopia
Shanghai, Shanghai Municipality, China
View Trial Details